308 related articles for article (PubMed ID: 33537004)
21. Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
Lu J; Chatain GP; Bugarini A; Wang X; Maric D; Walbridge S; Zhuang Z; Chittiboina P
J Clin Endocrinol Metab; 2017 Aug; 102(8):2825-2835. PubMed ID: 28505327
[TBL] [Abstract][Full Text] [Related]
22. Feasibility analysis of ACTH adenoma model in USP8-/- mice.
Li J; Wu N; Zhu D; Zhu Y
Endokrynol Pol; 2023; 74(2):181-189. PubMed ID: 36916541
[TBL] [Abstract][Full Text] [Related]
23. HSP90 as a novel therapeutic target for posterior capsule opacification.
Li J; Xue W; Wang X; Huang W; Wang XX; Li H; Cui X; Li M; Mu H; Ren Y; Zhang F; Hu Y
Exp Eye Res; 2019 Dec; 189():107821. PubMed ID: 31589841
[TBL] [Abstract][Full Text] [Related]
24. CRH stimulation improves
Boyle J; Patronas NJ; Smirniotopoulos J; Herscovitch P; Dieckman W; Millo C; Maric D; Chatain GP; Hayes CP; Benzo S; Scott G; Edwards N; Ray Chaudhury A; Lodish MB; Sharma S; Nieman LK; Stratakis CA; Lonser RR; Chittiboina P
Endocrine; 2019 Jul; 65(1):155-165. PubMed ID: 31062234
[TBL] [Abstract][Full Text] [Related]
25. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
[TBL] [Abstract][Full Text] [Related]
26. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells.
Karkoulis PK; Stravopodis DJ; Margaritis LH; Voutsinas GE
BMC Cancer; 2010 Sep; 10():481. PubMed ID: 20828379
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
[TBL] [Abstract][Full Text] [Related]
28. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease.
Tabuchi Y; Kitamura T; Fukuhara A; Mukai K; Onodera T; Miyata Y; Hamasaki T; Oshino S; Saitoh Y; Morii E; Otsuki M; Shimomura I
Endocr J; 2016 Jun; 63(6):545-54. PubMed ID: 27025408
[TBL] [Abstract][Full Text] [Related]
29. Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas.
Sekizaki T; Kameda H; Nakamura A; Kuwabara S; Nomoto H; Cho KY; Ishi Y; Motegi H; Miyoshi H; Atsumi T
Pituitary; 2023 Oct; 26(5):597-610. PubMed ID: 37642928
[TBL] [Abstract][Full Text] [Related]
30. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
Li Y; Zhang T; Schwartz SJ; Sun D
Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
[TBL] [Abstract][Full Text] [Related]
31. Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.
Jian F; Chen Y; Ning G; Fu W; Tang H; Chen X; Zhao Y; Zheng L; Pan S; Wang W; Bian L; Sun Q
Oncotarget; 2016 Feb; 7(8):9175-87. PubMed ID: 26824322
[TBL] [Abstract][Full Text] [Related]
32. Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas.
Pecori Giraldi F; Cassarino MF; Sesta A; Lasio G; Losa M
Neuroendocrinology; 2023; 113(6):606-614. PubMed ID: 36791678
[TBL] [Abstract][Full Text] [Related]
33. Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].
Kageyama K; Oki Y; Nigawara T; Suda T; Daimon M
Endocr J; 2014; 61(10):941-8. PubMed ID: 24974880
[TBL] [Abstract][Full Text] [Related]
34. Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease.
Weigand I; Knobloch L; Flitsch J; Saeger W; Monoranu CM; Höfner K; Herterich S; Rotermund R; Ronchi CL; Buchfelder M; Glatzel M; Hagel C; Fassnacht M; Deutschbein T; Sbiera S
J Clin Endocrinol Metab; 2019 Jul; 104(7):2535-2546. PubMed ID: 30844069
[TBL] [Abstract][Full Text] [Related]
35. Cushing's disease: towards precision medicine.
Kaiser UB
Cell Res; 2015 Jun; 25(6):649-50. PubMed ID: 25930709
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
37. Decoding the genetic basis of Cushing's disease: USP8 in the spotlight.
Theodoropoulou M; Reincke M; Fassnacht M; Komada M
Eur J Endocrinol; 2015 Oct; 173(4):M73-83. PubMed ID: 26012588
[TBL] [Abstract][Full Text] [Related]
38. Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.
Watanabe G; Behrns KE; Kim JS; Kim RD
Cancer Chemother Pharmacol; 2009 Aug; 64(3):433-43. PubMed ID: 19082595
[TBL] [Abstract][Full Text] [Related]
39. USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs.
Treppiedi D; Di Muro G; Marra G; Barbieri AM; Mangili F; Catalano R; Serban A; Ferrante E; Locatelli M; Lania AG; Arosio M; Spada A; Peverelli E; Mantovani G
Endocr Relat Cancer; 2021 Jun; 28(8):573-582. PubMed ID: 34086599
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.
Ebisawa T; Tojo K; Tajima N; Kamio M; Oki Y; Ono K; Sasano H
Endocr Pathol; 2008; 19(4):252-60. PubMed ID: 19048413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
